Recombinant Human Granulocyte Conoly Stimulating Factor


  • Neutropenia resulting from the cancer chemotherapy
  • Tromoting of neutrophil increase after bone marrow transplantation
  • Myelodyplasia syndrome and aplastic anemia
  • Congenital neutropenia, idiopathic neutropenia, Myelodyspastic syndrome with neutropenia and Periodic neutropenia

Te'erjin™ (filgrastim, rHuG-CSF) is used to

  • prevent infection in cancer patients undergoing certain types of chemotherapy and bone marrow transplants.
  • mobilize progenitor cells for collection in peripheral blood progenitor cell transplants, for treatment of severe chronic neutropenia.
  • support treatment of patients with acute myeloid leukemia.

Te'erjin™ finished its clinical trial in October 1999. The results show that Te'erjin™ is a safe and effective cytokine to reduce the incidence of infection and the duration of hospitalization and antibiotic use; increase the probability of maintaining the planned dose of chemotherapy on time and reduce the risks associated with chemotherapy-induced neutropenia.

  • P.R.C. Government License
    No. XIATEBAO S19990040; S19990041; S19990042
  • China Certification of GMP for Human Drugs (No. B0272)

Related link: